Search over 3,000 reports

    Glucagon-Like Peptide (GLP) Agonist -Pipeline Insight, 2017

    Glucagon-Like Peptide (GLP) Agonist -Pipeline Insight, 2017
    Date: Jan, 2018
    Type: Pharmaceutical Industry Report
    Pages: 90
    Geography: Global
    Delivery Timeline: 48 hrs
    SKU: DIMA0221
    "Glucagon-Like Peptide (GLP) Agonist -Pipeline Insight, 2018" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Glucagon-Like Peptide (GLP) Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

    Pipeline Products covered across the following Developmental Stages
    • Clinical
    • Non-clinical
    • Inactive: Discontinued and/or Dormant

    Descriptive coverage of pipeline development activities for Glucagon-Like Peptide (GLP) Agonist
    Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

    Pipeline Therapeutics assessment of products for Glucagon-Like Peptide (GLP) Agonist
    The report assesses the active Glucagon-Like Peptide (GLP) Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
    Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope of the report
    • Provides a snapshot of the therapeutics pipeline activity for Glucagon-Like Peptide (GLP) Agonist
    • Features the Glucagon-Like Peptide (GLP) Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages
    • Offers detailed therapeutic product profiles of Glucagon-Like Peptide (GLP) Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    • Coverage of dormant and discontinued pipeline projects across Glucagon-Like Peptide (GLP) Agonist

    Reasons to Buy
    • Establish a comprehensive understanding of the current pipeline scenario across Glucagon-Like Peptide (GLP) Agonist to formulate effective R&D strategies
    • Assess challenges and opportunities that influence Glucagon-Like Peptide (GLP) Agonist research & development (R&D)
    • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    • Identify and understand the sought after therapy areas and indications for Glucagon-Like Peptide (GLP) Agonist
    • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
    • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Glucagon-Like Peptide (GLP) Agonist to enhance and expand business potential and scope
    • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
    • Our extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
    1. Report Introduction
    2. Glucagon-Like Peptide (GLP) Agonist - Overview
    3. Pipeline Therapeutics
    • An Overview of Pipeline Products for Glucagon-Like Peptide (GLP) Agonist
    4. Comparative Analysis
    5. Glucagon-Like Peptide (GLP) Agonist Pipeline Products in Clinical Stages
    5.1 Drug Name : Company Name
    • Product Description
    • Research and Development
    • Product Development Activities
    Other product profiles in the detailed report…..
    6. Glucagon-Like Peptide (GLP) Agonist Pipeline Products in Non-clinical Stages
    6.1 Drug Name : Company Name
    • Product Description
    • Research and Development
    • Product Development Activities
    Other product profiles in the detailed report…..
    7. Therapeutic Assessment: Active Products
    • Pipeline Assessment by Route of Administration
    • Pipeline Assessment by Stage and Route of Administration
    • Pipeline Assessment by Molecule Type
    • Pipeline Assessment by Stage and Molecule Type
    8. Inactive Pipeline Products
    8.1 Drug Name : Company Name
    • Product Description
    • Research and Development
    • Product Development Activities
    • Reason for dormancy/discontinuation
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Note: Certain sections of the table of contents would vary according to the availability of information
    Table 1: Total Pipeline Products for Glucagon-Like Peptide (GLP) Agonist
    Table 2: Glucagon-Like Peptide (GLP) Agonist Therapeutic Products in Clinical Stages
    Table 3: Glucagon-Like Peptide (GLP) Agonist Therapeutic Products in Non-clinical Stages
    Table 4: Pipeline Assessment by Route of Administration
    Table 5: Pipeline Assessment by Stage and Route of Administration
    Table 6: Pipeline Assessment by Molecule Type
    Table 7: Pipeline Assessment by Stage and Molecule Type
    Table 8: Discontinued Products
    Table 9: Dormant Products
    Figure 1: Total Products for Glucagon-Like Peptide (GLP) Agonist
    Figure 2: Glucagon-Like Peptide (GLP) Agonist Therapeutic Products in Clinical Stages
    Figure 3: Glucagon-Like Peptide (GLP) Agonist Therapeutic Products in Non-clinical Stages
    Figure 4: Pipeline Analysis by Route of Administration
    Figure 5: Pipeline Analysis by Stage and Route of Administration
    Figure 6: Pipeline Analysis by Molecule Type
    Figure 7: Pipeline Analysis by Stage and Molecule Type
    Figure 8: Discontinued Products
    Figure 9: Dormant Products
    Glucagon-Like Peptide (GLP) Agonist drugs

    Glucagon-Like Peptide (GLP) Agonist companies

    Glucagon-Like Peptide (GLP) Agonist pipeline drugs

    Glucagon-Like Peptide (GLP) Agonist therapies

    Glucagon-Like Peptide (GLP) Agonist drugs under development

    Glucagon-Like Peptide (GLP) Agonist Phase products

    Glucagon-Like Peptide (GLP) Agonist Phase III

    Glucagon-Like Peptide (GLP) Agonist Phase II

    Glucagon-Like Peptide (GLP) Agonist Phase I

    Glucagon-Like Peptide (GLP) Agonist Pre-clinical

    Glucagon-Like Peptide (GLP) Agonist Discovery

    Glucagon-Like Peptide (GLP) Agonist research and development

    Glucagon-Like Peptide (GLP) Agonist discovery

    Glucagon-Like Peptide (GLP) Agonist NDA filed

    Glucagon-Like Peptide (GLP) Agonist Investigational New Drug Application

    Glucagon-Like Peptide (GLP) Agonist Collaboration Companies

    Glucagon-Like Peptide (GLP) Agonist Licensing

    Glucagon-Like Peptide (GLP) Agonist Patents

    Glucagon-Like Peptide (GLP) Agonist technology

    Glucagon-Like Peptide (GLP) Agonist ANDA

    Glucagon-Like Peptide (GLP) Agonist grants

    Glucagon-Like Peptide (GLP) Agonist financing

    • Single User License
      (20% Off)
      $1,500.00
    • Site License
      (30% Off)
      $3,000.00
    • Global License
      (40% Off)
      $4,500.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap